WO2006010507A2 - Substance bioresorbable pour le remplissage de defauts osseux - Google Patents

Substance bioresorbable pour le remplissage de defauts osseux Download PDF

Info

Publication number
WO2006010507A2
WO2006010507A2 PCT/EP2005/007768 EP2005007768W WO2006010507A2 WO 2006010507 A2 WO2006010507 A2 WO 2006010507A2 EP 2005007768 W EP2005007768 W EP 2005007768W WO 2006010507 A2 WO2006010507 A2 WO 2006010507A2
Authority
WO
WIPO (PCT)
Prior art keywords
bone
use according
substances
bioresorbable
powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2005/007768
Other languages
German (de)
English (en)
Other versions
WO2006010507A3 (fr
Inventor
Arne Briest
Ingo Mücke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ossacur AG
Original Assignee
Ossacur AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ossacur AG filed Critical Ossacur AG
Publication of WO2006010507A2 publication Critical patent/WO2006010507A2/fr
Publication of WO2006010507A3 publication Critical patent/WO2006010507A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
    • A61L27/3608—Bone, e.g. demineralised bone matrix [DBM], bone powder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3641—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the site of application in the body
    • A61L27/3645—Connective tissue
    • A61L27/365—Bones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/58—Materials at least partially resorbable by the body

Definitions

  • the present invention relates to a bioresorbable material for filling bone defects.
  • Bone defects are to be treated in many areas of medical care, especially in orthopedics, accident surgery, maxillofacial surgery and hand surgery. Bone defects occur, for example, in fractures, in particular in debris fractures, in the clearance of cysts and tumors, in osteoporosis, in the use of hip joint prostheses, in degenerative diseases of the spine and in tooth extractions, root tip resections, partial epidural reconstructions and peridontal defects. Often it makes sense to fill up bone defects in order to replace the original Knochen ⁇ material or to stimulate the regeneration of new bone and bone. To fill bone defects, a large number of different materials are already being used. For example, fully synthetic bone substitutes based on calcium phosphate or transplants of natural bone or bone fragments are used.
  • the material which is used to replenish the Knochende Stamme- ⁇ allows the reconstruction autologous bone, so that the external material can be more or less completely replaced by Consequentlyei ⁇ antigenic material support after some time. Therefore, the ability of the filler to be absorbed by the body plays a major role.
  • Previously used bones, bone splits or inorganic Knochener ⁇ set materials have the disadvantage that the absorption takes a very long time.
  • the absorption of the inorganic portion of the filler is the speed-determining step.
  • the invention therefore has as its object to provide a material for filling bone defects, which essentially corresponds to the natural bone composition, but nevertheless is degradable well and at relatively high speed.
  • This material should have osteoconductive properties, ie provide a support structure for the reconstruction of endogenous bones.
  • this filling material with osteoinductive properties, ie with properties which promote and support the formation of endogenous bone or cartilage tissue in a particular manner or with properties which are otherwise advantageous.
  • a demineralized xenogenic bone material is used as bioresorbable material for filling bone defects.
  • a demineralized bone material is a so-called bone matrix, from which the inorganic portion (minerals) is almost completely removed except for traces.
  • DBM demineralized bone matrix
  • the bone material used according to the invention therefore essentially consists only of the organic matrix, which, however, largely corresponds to the natural composition of the bone.
  • a natural bone consists of inorganic components, mainly hydroxyapatite. In addition to about 10% of water, the remaining 20% of organic constituents are formed, these being mainly collagen. To a small extent, non-collagenous proteins, in particular osteocalcin, osteonectin and osteopontin, cytokines, growth factors, proteoglycans and fats are present.
  • the demineralized bone material used according to the invention therefore essentially represents a mixture of various proteins (proteins) whose main component is collagen.
  • proteins proteins
  • these are mainly collagen type I.
  • Conventionally already used collagen sponges are generally prepared from skin or tendons. They also consist at least partly of collagen type I, which may be present in the native state. In these products, however, the "natural environment" is destroyed
  • the proteins of the demineralized bone material used according to the invention are in the natural state, environment and composition of the proteins of the bone material used according to the invention - A -
  • the demineralized bone material used in accordance with the invention comes very close in its composition and structure to natural bone and thus to ideal osteoconductive proteins owns properties. This material is therefore particularly advantageous for the filling of bone defects.
  • the demineralized bone material used according to the invention as an organic matrix in the body is rapidly degraded and thus enables and promotes the formation of endogenous bone material in a special way.
  • the demineralized bone material used according to the invention is xenogenic material, ie bone material of a foreign origin.
  • xenogenic material ie bone material of a foreign origin.
  • allogeneic material no human bone (allogeneic material) is used as starting material for the production of the bioabsorbable material.
  • Bone material xenogeneic origin generally has no or only a few pathogens that could be dangerous for humans.
  • Xenogenic material is therefore less risky than allogeneic material, since human pathogens are relatively rare in xenogeneic material.
  • the bone material used is degreased.
  • the fat content of the natural bone composition can be reduced or almost completely removed.
  • Such degreasing can be carried out before or after the demineralization of the bone material.
  • the processes of demineralization and degassing effectively also inactivate the transmissible pathogens possibly contained in the xenogenic source material.
  • the material can be produced by grinding bone, demineralizing in particular with acid, extracting with guanidine and further working up of the insoluble fraction of the demineralized material to establish a tissue-compatible environment.
  • the material can be degreased at any time prior to further processing to adjust the tissue-compatible environment with preferably organic solvent.
  • this degreasing step takes place before or after demineralization with acid.
  • Milling of the bone to bone meal is carried out according to methods familiar to the person skilled in the art. It is particularly advantageous that the resulting bone meal has a particle size range of about 30 to about 3,000 ⁇ m, preferably about 100 to about 2,000 ⁇ m.
  • the bone can be ground and / or sieved accordingly.
  • the degreasing is preferably carried out with the aid of ethanol and / or acetone.
  • Hydrochloric acid is preferably used for demineralization (decalcification).
  • extraction with guanidine is carried out.
  • the extraction with guanidine dissolves part of the otherwise insoluble bone matrix, primarily a part of the collagen and low molecular weight proteins.
  • the insoluble fraction is worked up further in accordance with the above description.
  • This extraction reduces the osteoinductivity of the resulting material, which may be advantageous depending on the desired application.
  • materials are thereby produced whose osteoconductive properties are in the foreground. These materials can be specifically modified by the addition of further substances in their properties.
  • the extraction step can advantageously be used to remove or inactivate possibly present transmissible pathogens.
  • the further work-up of the material is advantageous in order to be able to provide a tissue-friendly product which is well worn by the patient.
  • conditioning process chemicals are mainly removed. This can advantageously be carried out in such a way that the resulting particles are washed free of chemicals and neutral with water, saline water and / or buffer.
  • the resulting moist material can be adjusted in dry matter content. It can be moist or dry.
  • all animals with skeletal system come into question as source for the xenogenic bone material.
  • Cow, horse or pig, ie bovine, equine or porcine starting material are particularly preferred.
  • all types of bones of the skeleton can be used, in particular long bones, above all the cortex of the long bones.
  • the bioresorbable material is used as a powder for the application in front.
  • Powder here is to be understood as meaning a material in which the bone meal particles are essentially present next to one another. Particular preference is given to powders having a particle size of between about 30 and about 3,000 ⁇ m, in particular between about 100 and about 2,000 ⁇ m. The particle size can be adjusted either by suitable implementation of the bone milling process and / or by sieving the resulting particles.
  • the bioresorbable material is present as granules for the application.
  • a granulate consists of granules lat grains. Such a granular grain is produced by storing several bone meal particles together to form a superordinate structure. These may, for example, be spherical shapes. A granular comet is therefore in principle a small shaped body which can be round or rounded.
  • Granules can be produced, for example, by thermal and / or pressing pressure treatment from bone meal, ie from a powder. In this case, a pressure is to be understood by pressing pressure, which pressure is built up within a press.
  • the particle size of the bone meal or the powder or granules can be adjusted to a defined size range. The particle size distribution can be chosen differently for different applications.
  • the material is present as a shaped body.
  • moldings are aggregates of bone meal particles with definier ⁇ ter shape, for example, blocks, cuboids, slices or the like to understand. It can create moldings of any shape.
  • the moldings can be adapted to the defects to be filled out by mechanical processing by the user. "Granules and shaped bodies essentially differ only in size.
  • a shaped body can also be produced by thermal and / or pressing pressure treatment of powder or granules.
  • bioresorbable material as a powder, as a granule or as a shaped article depends essentially on the particular application, the method of treatment and the stability to be required. Powders or granules are especially suitable for the filling of small bone defects. For larger defects, it may be advantageous to use a shaped body, which is optionally adapted accordingly by the user.
  • a particular advantage of the use according to the invention of the bioabsorbable material lies in its porosity.
  • the porosity By the expression of the porosity, the vulnerability is influenced by the body's own factors, in particular by cells. In this way, the degradability in the body is influenced.
  • a majority of the pores of the material is in the size range over 100 microns. These pores are thus optimally suitable for ingrowth of cells. This promotes the integration of the filling material in the body as well as its degradation or absorption. Interconnecting, ie substantially continuous, pores are particularly advantageous.
  • the pores in the materials are essentially generated by the particle size distribution of the bone meal.
  • the porosity of the granules is also determined by the treatment conditions for the preparation of the granules, especially temperature and time. In addition to the pores that are present in the granules themselves, in a bulk granule, there are also interspaces between the individual granules, which can be varied by the shape of the granules.
  • the porosity of moldings is on the one hand by the grain size of the starting material and on the other by the pressing pressure and the - -
  • the porosity can be defined and adapted to the respective conditions of use. As already mentioned, pore sizes of about 100 ⁇ m and larger are particularly advantageous.
  • the stability especially of the granules and moldings can also be influenced by the production conditions. Important factors here are the particle size of the starting material, the pressure in particular in the production of moldings and the other conditions of manufacture, especially temperature and time.
  • the material is dried or is in dry form, in particular if it is present as a shaped body.
  • a dry and a moist form of delivery may be preferred.
  • the material ultimately used is dried or is in dry form.
  • the presence in dry form is particularly advantageous in terms of stability and durability, since the product moisture generally adversely affects the stability and durability.
  • the material is preferably present as a wet mass. Hier ⁇ by an agglomeration and thus a substantially stable intermediate form is achieved, which can be further stabilized by further treatment.
  • Drying can be carried out, for example, by lyophilization and / or by air drying.
  • the drying can be supported by Temperatur ⁇ application and / or vacuum.
  • the drying can - -
  • a demineralized and defatted bone material is made at low temperatures under vacuum.
  • a free-flowing powder can be produced.
  • a suitable device for example a granulating plate, with subsequent drying, a granule having different particle sizes can be prepared.
  • a lyophilized material often differ from the properties of a temperature treated material.
  • a shaped body produced from lyophilized material has a relatively low stability, so that the addition of binders for the production of the shaped body can be advantageous.
  • the material is sterilized or is present in sterilized form.
  • sterilization conventional methods come into question.
  • the bioresorbable material can be irradiated, in particular with radioactive rays, and / or gassed, in particular with ethylene oxide.
  • the bioresorbable material is provided with additives, active substances and / or extracts (see below), it must generally be taken into account that the sterilization measures the effectiveness of the substances used Can affect substances.
  • the antibiotic gentamycin in the bioresorbable material it is advantageous to sterilize by gassing with ethylene oxide.
  • aseptic preparation of the bioresorbable material is advantageous, as this can prevent problems during sterilization.
  • the bioresorbable material is present in packaged form. It is particularly preferred if the material is packed sterile. Within such a package, the material can be shipped and / or stored. During the actual application, the material can be removed from the packaging in a simple manner and used. In order to achieve sterility, it may be provided, for example, that the body is sterilized before packaging or even inside the packaging, for example by irradiation. Suitable materials for packaging are various materials, for example plastic casings or the like. As packaging u. a. also special syringes, in which the piston does not end or only in a slight rejuvenation.
  • the moist bioresorbable material which can be adjusted to a defined dry matter content, are filled and thus provided for the user in a practical manner.
  • additives and / or active ingredients can be added to the syringes before the actual filling.
  • the material is provided with at least one additive, active substance and / or extract.
  • the bioresorbable material used according to the invention is particularly advantageously suitable as a carrier for such additives, active substances, extracts or, for example, also for cells which likewise to be understood hereunder.
  • the properties of the material used according to the invention can be defined and adjusted by such substances in order to adapt the material according to the invention to the respective applications.
  • additives, agents or extracts are a variety of substances in question.
  • biologically active additives and / or active substances or biological extracts are particularly preferred. Such substances may be advantageous for product protection by z. B. prevent microbial degradation.
  • substances can be used which are advantageous for therapeutic reasons (drug delivery system) and / or in promoting bone healing and bone regeneration.
  • physical properties of the bioresorbable material used according to the invention can also be specifically modulated by additives.
  • the release of active ingredients from the material can be influenced by other additives.
  • Suitable active substances are in particular those substances which are locally effective and effect their effect in the immediate vicinity of the bone defect.
  • systemically active substances can also be introduced into the body through the bioresorbable material. This depends on the particular application and the defect to be treated.
  • a binder and / or a crosslinking agent can advantageously be used as additive or as active substance, whereby the modifi cation possibilities of the bioresorbable material are increased in a wide range.
  • the stability and / or the porosity of the material can be influenced.
  • binders influences the porosity. For example, when particles are merely agitated with the binder, porosity tends to be greatly reduced. If this is not desired, depending on the application, a superficial conditioning of the individual - -
  • the hydrophilicity of the bioresorbable material can be influenced.
  • Biological substances are particularly preferred as amphoteric agents.
  • a reconstitution agent can be provided as additive. This is particularly advantageous if the bioresorbable material is in dried form and is remoistened before use. The rewetting of dried biopolymers can be problematic since the biopolymers or the bioresorbable material may no longer have the desired properties after rewetting.
  • substances which are advantageous in the reconstitution and which, after addition of, for example, water or physiological saline solution, produce the desired consistency and the desired properties of the bioresorbable material.
  • substances which generally influence the consistency of the bioresorbable material can be used as additives.
  • substances come into question with which the viscosity can be set in a defined manner.
  • salts are suitable, in particular salts of anionic or cationic polymers and / or biopolymers.
  • the bioresorbable material itself can be protected, in particular against bacterial decomposition.
  • the bioresorbable material can hereby be provided with specific functions which unfold advantageous action in the body of the patient. This can be done, for example, for therapeutic reasons and / or to support the nodules. healing and / or regeneration. As a result, the material can be provided with osteoinductive properties.
  • the bone and / or cartilage renewal can be induced or promoted, which speeds up the integration and healing processes in the patient.
  • Suitable growth factors are, for example, BMP ⁇ bovine morphogenetic protein), in particular BMP-2, BMP-7 and / or BMP-4, and IGF (insuline-like growth factor, in particular IGF-I, and TGF (transforming growth factor)
  • the bioresorbable material may be provided with one or more cytostatics, which is particularly advantageous in the case of cancerous changes in the region of the bone defect and / or the surrounding tissue
  • the use of antibiotics as the active ingredient is preferred, which on the one hand can avoid defense reactions in the body, and on the other hand can also protect the bioabsorbable material from product damage
  • the use of antibodies in this context may be useful, in particular a for therapeutic reasons.
  • the bioresorbable material may be provided with an extract, in particular a biological extract.
  • an extract may contain, for example, a combination of various active substances which may be biologically active.
  • Such an extract is preferably obtained from biological material.
  • it is an extract of demineralized bone material containing various, especially biologically active, substances which are very active with regard to bone or cartilage formation.
  • Such an extract is sold as a product by the applicant under the trade name "COLLOSS.”
  • such an extract can be used in combination with other active substances, in particular with other biologically active substances.
  • the additives, active ingredients and / or extracts can be mixed with the bioabsorbable material, which is present for example from powder, and thus made available for use.
  • bioabsorbable material which is present for example from powder, and thus made available for use.
  • demineralized and in particular also defatted and / or further extracted bone material can advantageously be coated with an extract, in particular with the mentioned "COLLOSS.”
  • Shaped articles are particularly suitable for such a coating means for the use of "COLLOSS" according to the cited patent applications that the final stage resulting from the production of the extract is used prior to lyophilization.
  • a coating of this kind can be used to produce a bioabsorbable material that is both osteoconductive and osteoinductive. It has an advantageous stability and has rapid resorbability, since no slowly resorbable inorganic material is present.
  • the pore structure is optimized not only between the individual particles but also within the particles, thereby providing an interconnecting porosity which is also accessible to cells within the particles. Due to the coating tion of the material, the extract with its active substances in the bone defect to be filled is distributed in an optimal manner. In particular, collapse of the material used is prevented by the stability of the particles.
  • the substances contained in the extract are advantageously presented on the inner and / or outer surface of the particles, so that these substances are available to the body, in particular to the body's own cells. This accessibility of the active substances is markedly improved, for example, in comparison with autologous bone as filling material.
  • the addition of the substances can take place before or after drying the material.
  • either the ready-to-bioresorbable material with the additives for the application can be provided, or the user is given the opportunity to coat the material himself or to coat the other substances.
  • This can be done by offering a kit containing all the essential components.
  • their stability should be taken into account with respect to the production conditions and the sterilization process. In the event that the user provides the product itself with appropriate substances, this advantageously must not be taken into account.
  • bioresorbable material By providing them with additives, active ingredients and / or extracts, on the one hand outer surfaces of the bioresorbable material and on the other hand additionally or alternatively cavities or inner spaces of the bioresorbable material may be provided with the substances. It is particularly preferred if active substances are used in such a way that a controlled release is made possible. This can be done, for example, by the fact that interiors and / or pores of the bioresorbable material with the effective Sub- punched or modified so that the drug gebun ⁇ the and then released retarded.
  • the material used according to the invention can be provided as a kit for the application.
  • This kit comprises at least one demineralized xenogenic bone material and preferably at least one additive, active substance and / or an extract.
  • the user has the possibility of providing the demineralized xenogenic bone material which is used to fill bone defects with one or more active substances which may be adapted to the respective application. Therefore, various substances can be provided as additives, active ingredients and / or extracts in the kit, so that the user can select the respective suitable substance or substances.
  • the separate provision of demineralized xenogenic bone material and the other substances can enable increased storage stability.
  • the kit may, for example, also contain components which are suitable for rewetting or reconstitution of the material present in this case in dry form. These are, for example, sterile water, physiological saline or suitable buffers. Furthermore, in such a kit, other aids, such as tools, may be included, which can be used in the course of the application to the patient.
  • Moist demineralized, degreased and extracted with Gyanidiniumhydrochlorid bone matrix having a particle size of ⁇ 2,000 microns is spread over a large area in a bowl and dried at temperatures up to 200 0 C, especially at 40 to 120 0 C, for 2 to 40 hours. Subsequently, adhering particles are mechanically destroyed.
  • the powder can be fractionated and filled on a sieve into different particle sizes. After packaging into a suitable packaging, a sterile product is obtained after sterilization by conventional methods, in particular by irradiation.
  • a demineralized, degreased and extracted with guanidinium hydrochloride bone matrix with a particle size underside half of 2,000 microns used.
  • the wet matrix is placed in a press consisting of a 0.8 cm diameter tube and a flask. By compressing a moist shaped body of about 0.5 cm height is generated. This is followed by a Temperaturbe ⁇ treatment at up to 200 ° C, in particular at 40 to 120 ° C, for 2 to 40 hours.
  • a dry, porous, mechanically stable shaped body with dimensions of 0.5 mm (height) x 0.8 mm (diameter) won.
  • After packing in a suitable packaging is - -

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Botany (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Materials For Medical Uses (AREA)

Abstract

L'invention concerne l'utilisation d'une substance osseuse xénogène déminéralisée comme substance biorésorbable pour le remplissage de défauts osseux. De préférence, cette substance osseuse peut être en outre dégraissée et/ou extraite à la guanidine. Cette substance peut se présenter sous forme de poudre, de granulat ou de corps moulé.
PCT/EP2005/007768 2004-07-22 2005-07-16 Substance bioresorbable pour le remplissage de defauts osseux Ceased WO2006010507A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004036882.1 2004-07-22
DE200410036882 DE102004036882A1 (de) 2004-07-22 2004-07-22 Bioresorbierbares Material zur Füllung von Knochendefekten

Publications (2)

Publication Number Publication Date
WO2006010507A2 true WO2006010507A2 (fr) 2006-02-02
WO2006010507A3 WO2006010507A3 (fr) 2006-04-27

Family

ID=35520535

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/007768 Ceased WO2006010507A2 (fr) 2004-07-22 2005-07-16 Substance bioresorbable pour le remplissage de defauts osseux

Country Status (2)

Country Link
DE (1) DE102004036882A1 (fr)
WO (1) WO2006010507A2 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101822851A (zh) * 2010-06-21 2010-09-08 余方圆 一种组织工程骨软骨支架及其制备方法
WO2011029622A2 (fr) 2009-09-14 2011-03-17 Celgen Ag Mélange de granulés comprenant deux types de granulés différents pour distraction de cal artificielle
WO2012123095A1 (fr) 2011-03-14 2012-09-20 Celgen Ag Mélange de granulats, comprenant deux granulats différents, pour distraction de cal artificielle
US10327870B2 (en) 2016-03-31 2019-06-25 Ernesto A. Lee Method, devices and articles for conducting subperiosteal minimally invasive aesthetic jaw bone grafting augmentation
CN110075356A (zh) * 2019-03-28 2019-08-02 中国辐射防护研究院 一种用于外科治疗骨缺损的可塑性填充材料及其制备方法

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005034420A1 (de) * 2004-12-23 2006-07-06 Ossacur Ag Gelartiges Material zur Füllung von Knochen- und/oder Knorpeldefekten

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4627853A (en) * 1985-05-29 1986-12-09 American Hospital Supply Corporation Method of producing prostheses for replacement of articular cartilage and prostheses so produced
US4678470A (en) * 1985-05-29 1987-07-07 American Hospital Supply Corporation Bone-grafting material
US5250302A (en) * 1988-04-08 1993-10-05 Stryker Corporation Osteogenic devices
US4975526A (en) * 1989-02-23 1990-12-04 Creative Biomolecules, Inc. Bone collagen matrix for zenogenic implants
US5061286A (en) * 1989-08-18 1991-10-29 Osteotech, Inc. Osteoprosthetic implant
US5236456A (en) * 1989-11-09 1993-08-17 Osteotech, Inc. Osteogenic composition and implant containing same
EP0483944B1 (fr) * 1990-10-31 1995-07-05 El Gendler Membranes flexibles produites à partir d'une matrice osseuse organique pour la réparation et reconstruction du squelette
US5507813A (en) * 1993-12-09 1996-04-16 Osteotech, Inc. Shaped materials derived from elongate bone particles
US5674292A (en) * 1995-06-07 1997-10-07 Stryker Corporation Terminally sterilized osteogenic devices and preparation thereof
US20020076429A1 (en) * 1998-01-28 2002-06-20 John F. Wironen Bone paste subjected to irradiative and thermal treatment
WO1999047080A1 (fr) * 1998-03-16 1999-09-23 Crosscart, Inc. Xenogreffes osseuses
US6340477B1 (en) * 2000-04-27 2002-01-22 Lifenet Bone matrix composition and methods for making and using same
DE10026306A1 (de) * 2000-05-26 2001-11-29 Tutogen Medical Gmbh Transplantat

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011029622A2 (fr) 2009-09-14 2011-03-17 Celgen Ag Mélange de granulés comprenant deux types de granulés différents pour distraction de cal artificielle
DE102009042493A1 (de) 2009-09-14 2011-04-21 Celgen Ag Granulatmischung, umfassend zwei verschiedene Granulate, zur künstlichen Kallusdistraktion
EP2810666A1 (fr) 2009-09-14 2014-12-10 CelGen3D AG Mélange de granulés comprenant deux types de granulés différents pour la distraction tridimensionnelle de cal artificielle
CN101822851A (zh) * 2010-06-21 2010-09-08 余方圆 一种组织工程骨软骨支架及其制备方法
WO2012123095A1 (fr) 2011-03-14 2012-09-20 Celgen Ag Mélange de granulats, comprenant deux granulats différents, pour distraction de cal artificielle
DE102011014789A1 (de) 2011-03-14 2012-09-20 Celgen Ag Granulatmischung, umfassend zwei verschiedene Granulate, zur künstlichen Kallusdistraktion
US10327870B2 (en) 2016-03-31 2019-06-25 Ernesto A. Lee Method, devices and articles for conducting subperiosteal minimally invasive aesthetic jaw bone grafting augmentation
CN110075356A (zh) * 2019-03-28 2019-08-02 中国辐射防护研究院 一种用于外科治疗骨缺损的可塑性填充材料及其制备方法

Also Published As

Publication number Publication date
DE102004036882A1 (de) 2006-02-16
WO2006010507A3 (fr) 2006-04-27

Similar Documents

Publication Publication Date Title
DE69735625T2 (de) Verfahren zur herstellung flexibler schichten aus deminaralisierten,länglichen knochenpartikeln
DE60020526T2 (de) Osteogene pastenzusammensetzungen und ihre verwendung
DE60026586T2 (de) Zellulare matrix
DE69024970T2 (de) Verfahren zur herstellung eines werkstoffes für osteoplastik aus natürlichem knochengewebe sowie aus solchem verfahren gewonnenes material
DE69633197T2 (de) Osteogene vorrichtungen und methode zur herstellung derselben
DE19953771C1 (de) Resorbierbares Knochen-Implantatmaterial sowie Verfahren zur Herstellung desselben
DE69118505T2 (de) Knochenbildende Zusammensetzung und ein diese enthaltendes Implantat
DE60006356T2 (de) Hochmineralisierte osteogene schwammzusammensetzungen und ihre verwendung
DE69430069T2 (de) Förmige materialien auf der basis von länglichen knochenteilchen und verfahren zu ihrer herstellung
US7335381B2 (en) Transplantable particulate bone composition having high osteoinductive capacity and methods for making and using same
DE69626205T2 (de) Terminal-sterilisierte osteogene vorrichtungen und ihre herstellung
EP0141004B1 (fr) Matériau de remplacement des os à base d'os naturels
DE10134514A1 (de) Gemisch aus Knochenmaterial und Collagen zur Reparatur von verletzten Gelenken
DE68927740T2 (de) Chemische verbindungen
EP0925076B1 (fr) Procede de production d'un implant compose d'un materiau support resorbable renfermant une pharmaceutice, un antibiotique, un cytostatique ou une hormone
EP1523342A1 (fr) Composites structures en tant que matrice pour la production de tissus osseux par ingenierie genetique
US20170119933A1 (en) Bone void filler having sustained therapeutic agent release
EP3367974B1 (fr) Matériau de remplissage de cavités osseuses ayant des revêtements de calcium
DE102009037479A1 (de) Verfahren zur Herstellung eines biokompatiblen und bioabbaubaren Kompositmaterials, das danach erhältliche Kompositmaterial sowie dessen Verwendung als Medizinprodukt
WO2006010507A2 (fr) Substance bioresorbable pour le remplissage de defauts osseux
WO2006010547A2 (fr) Matiere bioresorbable destinee a remplir les defauts osseux
DE112016001386B4 (de) Kohlenstoffpartikel und Komposite derselben für die Regeneration von Skelettmuskelgewebe und Weichgewebe
WO2001059068A2 (fr) Copeaux osseux artificiels, procedes permettant de les produire et utilisation
DE60025278T2 (de) Volumenstabile osteoinduktive / osteokonduktive zusammensetzungen
EP1819371A2 (fr) Materiau bioresorbable et mineralise pour combler des defauts osseux

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase